1
|
Leciejewska N, Jędrejko K, Gómez-Renaud VM, Manríquez-Núñez J, Muszyńska B, Pokrywka A. Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases. Eur J Clin Pharmacol 2024; 80:185-202. [PMID: 38059982 PMCID: PMC10847181 DOI: 10.1007/s00228-023-03592-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Accepted: 11/02/2023] [Indexed: 12/08/2023]
Abstract
PURPOSE Selective androgen receptor modulators (SARMs) have demonstrated agonist activity on the androgen receptor in various tissues, stimulating muscle mass growth and improving bone reconstruction. Despite being in clinical trials, none has been approved by the Food and Drug Administration (FDA) or European Medicines Agency for pharmacotherapy. Still, SARMs are very popular as performance-enhancing drugs. The FDA has issued warnings about the health risks associated with SARMs, but the long-term exposure and possible adverse events still need to be fully understood. This review aims to evaluate the adverse events associated with using SARMs by humans. METHODS PubMed database was searched from September 16, 2022, to October 2, 2023. In total, 20 records were included in the final review. Data from preclinical and clinical studies supported the review. RESULTS Since 2020, 20 reports of adverse events, most described as drug-induced liver injury associated with the use of SARM agonists, have been published. The main symptoms mentioned were cholestatic or hepatocellular liver injury and jaundice. Limited data are related to the dosages and purity of SARM supplements. CONCLUSION Promoting SARMs as an anabolic agent in combination with other performance-enhancing drugs poses a risk to users not only due to doping controls but also to health safety. The lack of quality control of consumed supplements makes it very difficult to assess the direct impact of SARMs on the liver and their potential hepatotoxic effects. Therefore, more detailed analyses are needed to determine the safety of using SARMs.
Collapse
Affiliation(s)
- Natalia Leciejewska
- Department of Animal Physiology, Biochemistry and Biostructure, Poznań University of Life Sciences, 60-637, Poznan, Poland
| | - Karol Jędrejko
- Department of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688, Kraków, Poland.
| | - Víctor M Gómez-Renaud
- Human Performance Laboratory, School of Physical Education, Autonomous University of Nuevo Leon, San Nicolas de los Garza, Mexico
| | - Josué Manríquez-Núñez
- Department of Research and Graduate Studies in Food Sciences, School of Chemistry, Autonomous University of Queretaro, Santiago de Queretaro, Mexico
| | - Bożena Muszyńska
- Department of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688, Kraków, Poland
| | - Andrzej Pokrywka
- Department of Biochemistry and Pharmacogenomics, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland
| |
Collapse
|
2
|
Wagener F, Naumann N, Göldner V, Görgens C, Guddat S, Karst U, Thevis M. Comparison of in vitro approaches for predicting the metabolism of the selective androgen receptor modulator RAD140. Anal Bioanal Chem 2023; 415:5657-5669. [PMID: 37421437 PMCID: PMC10473985 DOI: 10.1007/s00216-023-04835-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2023] [Revised: 06/15/2023] [Accepted: 06/27/2023] [Indexed: 07/10/2023]
Abstract
The identification of metabolites allows for the expansion of possible targets for anti-doping analysis. Especially for novel substances such as selective androgen receptor modulators (SARMs), information on metabolic fate is scarce. Novel approaches such as the organ on a chip technology may provide a metabolic profile that resembles human in vivo samples more closely than approaches that rely on human liver fractions only. In this study, the SARM RAD140 was metabolized by means of subcellular human liver fractions, human liver spheroids in an organ on a chip platform, and electrochemical (EC) conversion. The resulting metabolites were analyzed with LC-HRMS/MS and compared to a human doping control urine sample that yielded an adverse analytical finding for RAD140. A total of 16 metabolites were detected in urine, while 14, 13, and 7 metabolites were detected in samples obtained from the organ on a chip experiment, the subcellular liver fraction, and EC experiments, respectively. All tested techniques resulted in the detection of RAD140 metabolites. In the organ on a chip samples, the highest number of metabolites were detected. The subcellular liver fractions and organ on a chip techniques are deemed complementary to predict metabolites of RAD140, as both techniques produce distinct metabolites that are also found in an anonymized human in vivo urine sample.
Collapse
Affiliation(s)
- Felicitas Wagener
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany
| | - Nana Naumann
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany
| | - Valentin Göldner
- Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany
- International Graduate School for Battery Chemistry, Characterization, Analysis, Recycling and Application (BACCARA), University of Münster, Münster, Germany
| | - Christian Görgens
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany
| | - Sven Guddat
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany
| | - Uwe Karst
- Institute of Inorganic and Analytical Chemistry, University of Münster, Münster, Germany
- International Graduate School for Battery Chemistry, Characterization, Analysis, Recycling and Application (BACCARA), University of Münster, Münster, Germany
| | - Mario Thevis
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
- European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne, Germany.
| |
Collapse
|
3
|
Investigations into the concentration and metabolite profiles of stanozolol and LGD-4033 in blood plasma and seminal fluid using liquid chromatography high-resolution mass spectrometry. Anal Bioanal Chem 2023; 415:669-681. [PMID: 36441233 PMCID: PMC9839828 DOI: 10.1007/s00216-022-04456-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 10/27/2022] [Accepted: 11/21/2022] [Indexed: 11/29/2022]
Abstract
Potential scenarios as to the origin of minute amounts of banned substances detected in doping control samples have been a much-discussed problem in anti-doping analysis in recent years. One such debated scenario has been the contamination of female athletes' urine with ejaculate containing doping agents and/or their metabolites. The aim of this work was to obtain complementary information on whether relevant concentration ranges of doping substances are excreted into the ejaculate and which metabolites can be detected in the seminal fluid (sf) and corresponding blood plasma (bp) samples. A method was established to study the concentration and metabolite profiles of stanozolol and LGD-4033-substances listed under anabolic substances (S1) on the World Anti-Doping Agency's Prohibited List-in bp and sf using liquid chromatography high-resolution mass spectrometry (LC-HRMS). For sf and bp, methods for detecting minute amounts of these substances were developed and tested for specificity, recovery, linearity, precision, and reliability. Subsequently, sf and bp samples from an animal administration study, where a boar orally received stanozolol at 0.33 mg/kg and LGD-4033 at 0.11 mg/kg, were measured. The developed assays proved appropriate for the detection of the target substances in both matrices with detection limits between 10 and 40 pg/mL for the unmetabolized drugs in sf and bp, allowing to estimate the concentration of stanozolol in bp (0.02-0.40 ng/mL) and in sf (0.01-0.25 ng/mL) as well as of LGD-4033 in bp (0.21-2.00 ng/mL) and in sf (0.03-0.68 ng/mL) post-administration. In addition, metabolites resulting from different metabolic pathways were identified in sf and bp, with sf resembling a composite of the metabolic profile of bp and urine.
Collapse
|
4
|
Wagener F, Euler L, Görgens C, Guddat S, Thevis M. Human In Vivo Metabolism and Elimination Behavior of Micro-Dosed Selective Androgen Receptor Modulator RAD140 for Doping Control Purposes. Metabolites 2022; 12:metabo12070666. [PMID: 35888790 PMCID: PMC9325264 DOI: 10.3390/metabo12070666] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 07/15/2022] [Accepted: 07/18/2022] [Indexed: 02/06/2023] Open
Abstract
RAD140 is a selective androgen receptor modulator which has been abused in sporting competitions. Its use is prohibited by the World Anti-Doping Agency (WADA) for athletes at all times. In addition to its illicit use, adverse analytical findings of RAD140 in doping control samples might result from other scenarios, e.g., the ingestion of contaminated dietary supplements. The differentiation between samples resulting from such contamination scenarios and intentional doping presents a considerable challenge, as little is known about the metabolism and elimination behavior of RAD140 in humans. In this study, six micro-dose excretion studies with five adult male volunteers each were conducted, and urine samples were analyzed by means of LC-HRMS/MS. Multiple metabolites, firstly detected in human urine, are described in this study. The sample preparation included an enzymatic hydrolysis step, which facilitated the estimation of RAD140 concentrations in urine. The elimination profiles and detection times for six metabolites as well as the intact drug are presented. The method was extensively characterized and deemed fit-for-purpose. The metabolite ratios were investigated for their predictive power in estimating the dose of RAD140 intake. The presented data will aid in better case result management in future doping cases involving RAD140.
Collapse
Affiliation(s)
- Felicitas Wagener
- Institute of Biochemistry/Center for Preventive Doping Research, German Sports University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany; (F.W.); (L.E.); (C.G.); (S.G.)
| | - Luisa Euler
- Institute of Biochemistry/Center for Preventive Doping Research, German Sports University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany; (F.W.); (L.E.); (C.G.); (S.G.)
| | - Christian Görgens
- Institute of Biochemistry/Center for Preventive Doping Research, German Sports University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany; (F.W.); (L.E.); (C.G.); (S.G.)
| | - Sven Guddat
- Institute of Biochemistry/Center for Preventive Doping Research, German Sports University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany; (F.W.); (L.E.); (C.G.); (S.G.)
| | - Mario Thevis
- Institute of Biochemistry/Center for Preventive Doping Research, German Sports University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany; (F.W.); (L.E.); (C.G.); (S.G.)
- European Monitoring Center for Emerging Doping Agents (EuMoCEDA), 50933 Cologne, Germany
- Correspondence:
| |
Collapse
|
5
|
Wagener F, Guddat S, Görgens C, Angelis YS, Petrou M, Lagojda A, Kühne D, Thevis M. Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes. Anal Bioanal Chem 2021; 414:1151-1162. [PMID: 34734312 PMCID: PMC8724150 DOI: 10.1007/s00216-021-03740-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Revised: 10/07/2021] [Accepted: 10/18/2021] [Indexed: 11/29/2022]
Abstract
LGD-4033 (ligandrol) is a selective androgen receptor modulator (SARM), which is prohibited in sports by the World Anti-Doping Agency (WADA) and led to 62 adverse analytical findings (AAFs) in 2019. But not only deliberate doping with LGD-4033 constitutes a problem. In the past years, some AAFs that concerned SARMs can be attributed to contaminated dietary supplements (DS). Thus, the urgency to develop methods to differentiate between inadvertent doping and abuse of SARMs to benefit from the performance-enhancing effect of the compound in sports is growing. To gain a better understanding of the metabolism and excretion patterns of LGD-4033, human micro-dose excretion studies at 1, 10, and 50 µg LGD-4033 were conducted. Collected urine samples were prepared for analysis using enzymatic hydrolysis followed by solid-phase extraction and analyzed via LC-HRMS/MS. Including isomers, a total of 15 phase I metabolites were detected in the urine samples. The LC-HRMS/MS method was validated for qualitative detection of LGD-4033, allowing for a limit of detection (LOD) of 8 pg/mL. The metabolite M1, representing the epimer of LGD-4033, was synthesized and the structure elucidated by NMR spectroscopy. As the M1/LGD-4033 ratio changes over time, the ratio and the approximate LGD-4033 concentration can contribute to estimating the time point of drug intake and dose of LGD-4033 in doping control urine samples, which is particularly relevant in anti-doping result management.
Collapse
Affiliation(s)
- Felicitas Wagener
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany
| | - Sven Guddat
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany
| | - Christian Görgens
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany
| | - Yiannis S Angelis
- Doping Control Laboratory of Athens, Institute of Biosciences & Applications, National Center for Scientific Research "Demokritos", Neratziotissis & Amaryssias Artemidos Str, 15123, Athens, Greece
| | - Michael Petrou
- Cyprus Anti-Doping Authority, Makarion Athletic Centre Avenue, Engomi, CY 2400, Nicosia, Cyprus
| | - Andreas Lagojda
- BayerCropScience AG, Alfred-Nobel-Str. 50, 40789, Monheim, Germany
| | - Dirk Kühne
- BayerCropScience AG, Alfred-Nobel-Str. 50, 40789, Monheim, Germany
| | - Mario Thevis
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany. .,European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany.
| |
Collapse
|
6
|
Walpurgis K, Rubio A, Wagener F, Krug O, Knoop A, Görgens C, Guddat S, Thevis M. Elimination profiles of microdosed ostarine mimicking contaminated products ingestion. Drug Test Anal 2020; 12:1570-1580. [DOI: 10.1002/dta.2933] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 07/30/2020] [Accepted: 09/11/2020] [Indexed: 12/11/2022]
Affiliation(s)
- Katja Walpurgis
- Center for Preventive Doping Research/Institute of Biochemistry German Sport University Cologne Cologne Germany
| | - Ana Rubio
- Center for Preventive Doping Research/Institute of Biochemistry German Sport University Cologne Cologne Germany
| | - Felicitas Wagener
- Center for Preventive Doping Research/Institute of Biochemistry German Sport University Cologne Cologne Germany
| | - Oliver Krug
- Center for Preventive Doping Research/Institute of Biochemistry German Sport University Cologne Cologne Germany
| | - Andre Knoop
- Center for Preventive Doping Research/Institute of Biochemistry German Sport University Cologne Cologne Germany
| | - Christian Görgens
- Center for Preventive Doping Research/Institute of Biochemistry German Sport University Cologne Cologne Germany
| | - Sven Guddat
- Center for Preventive Doping Research/Institute of Biochemistry German Sport University Cologne Cologne Germany
| | - Mario Thevis
- Center for Preventive Doping Research/Institute of Biochemistry German Sport University Cologne Cologne Germany
- European Monitoring Center for Emerging Doping Agents (EuMoCEDA) Cologne/Bonn Germany
| |
Collapse
|
7
|
Temerdashev AZ, Dmitrieva EV. Methods for the Determination of Selective Androgen Receptor Modulators. JOURNAL OF ANALYTICAL CHEMISTRY 2020. [DOI: 10.1134/s1061934820070187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
8
|
Temerdashev A, Dmitrieva E, Azaryan A, Gashimova E. A novel approach to the quantification of urinary aryl‐propionamide‐derived SARMs by UHPLC–MS/MS. Biomed Chromatogr 2019; 34:e4700. [DOI: 10.1002/bmc.4700] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Revised: 09/09/2019] [Accepted: 09/13/2019] [Indexed: 02/06/2023]
Affiliation(s)
- Azamat Temerdashev
- Department of Analytical ChemistryKuban State University Krasnodar Russia
| | | | - Alice Azaryan
- Department of Analytical ChemistryKuban State University Krasnodar Russia
| | - Elina Gashimova
- Department of Analytical ChemistryKuban State University Krasnodar Russia
| |
Collapse
|
9
|
Fragkaki AG, Sakellariou P, Kiousi P, Kioukia-Fougia N, Tsivou M, Petrou M, Angelis Y. Human in vivo metabolism study of LGD-4033. Drug Test Anal 2018; 10:1635-1645. [PMID: 30255601 DOI: 10.1002/dta.2512] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2018] [Revised: 09/19/2018] [Accepted: 09/20/2018] [Indexed: 12/13/2022]
Abstract
Selective androgen receptor modulators (SARMs) are an emerging class of therapeutics targeted to cachexia, sarcopenia, and hypogonadism treatment. LGD-4033 is a SARM which has been included on the Prohibited List annually released by the World Anti-Doping Agency (WADA). The aim of the present work was the investigation of the metabolism of LGD-4033 in a human excretion study after administration of an LGD-4033 supplement, the determination of the metabolites' excretion profiles with special interest in the determination of its long-term metabolites, and the comparison of the excretion time of the phase I and phase II metabolites. The results were also compared to those derived from previous LGD-4033 studies concerning both in vitro and in vivo experiments. Supplement containing LGD-4033 was administered to one human male volunteer and urine samples were collected up to almost 21 days. Analysis of the hydrolyzed (with β-glucuronidase) as well as of the non-hydrolyzed samples was performed using liquid chromatography-high resolution mass spectrometry (LC-HRMS) in negative ionization mode and revealed that, in both cases, the two isomers of the dihydroxylated metabolite (M5) were preferred target metabolites. The gluco-conjugated parent LGD-4033 and its gluco-conjugated metabolites M1 and M2 can be also considered as useful target analytes in non-hydrolyzed samples. The study also presents two trihydroxylated metabolites (M6) identified for the first time in human urine; one of them was recently reported in an LGD-4033 metabolism study in horse urine and plasma.
Collapse
Affiliation(s)
- Argyro G Fragkaki
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece
| | - Panagiotis Sakellariou
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece.,Faculty of Biology, School of Science, National and Kapodistrian University of Athens, Panepistimioupolis, Zografou, 15771, Athens, Greece
| | - Polyxeni Kiousi
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece
| | - Nassia Kioukia-Fougia
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece
| | - Maria Tsivou
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece
| | - Michael Petrou
- Cyprus Anti-Doping Authority, Makarion Athletic Centre Avenue, Engomi, Nicosia, CY, 2400, Cyprus
| | - Yiannis Angelis
- Doping Control Laboratory of Athens, Olympic Athletic Center of Athens "Spyros Louis", 37 Kifisias Avenue, 15123, Maroussi, Greece
| |
Collapse
|
10
|
Thevis M, Schänzer W. Detection of SARMs in doping control analysis. Mol Cell Endocrinol 2018; 464:34-45. [PMID: 28137616 DOI: 10.1016/j.mce.2017.01.040] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Revised: 01/24/2017] [Accepted: 01/24/2017] [Indexed: 11/27/2022]
Abstract
The class of selective androgen receptor modulators (SARMs) has been the subject of intense and dedicated clinical research over the past two decades. Potential therapeutic applications of SARMs are manifold and focus particularly on the treatment of conditions manifesting in muscle loss such as general sarcopenia, cancer-associated cachexia, muscular dystrophy, etc. Consequently, based on the substantial muscle- and bone-anabolic properties of SARMs, these agents constitute substances with significant potential for misuse in sport and have therefore been added to the Word Anti-Doping Agency's (WADA's) Prohibited List in 2008. Since then, numerous adverse analytical findings have been reported for various different SARMs, which has underlined the importance of proactive and preventive anti-doping measures concerning emerging drugs such as these anabolic agents, which have evidently been misused in sport despite the fact that none of these SARMs has yet received full clinical approval. In this review, analytical data on SARMs generated in the context of research conducted for sports drug testing purposes are summarized and state-of-the-art test methods aiming at intact drugs as well as diagnostic urinary metabolites are discussed. Doping control analytical approaches predominantly rely on chromatography hyphenated to mass spectrometry, which have allowed for appropriately covering the considerable variety of pharmacophores present in SARMs such as the non-steroidal representatives ACP-105, BMS-564929, GLPG0492 (DT-200), LG-121071, LGD-2226, LGD-4033/VK 5211, ostarine/enobosarm, RAD-140, S-40503, etc. as well as steroidal compounds such as MK-0773 and YK-11.
Collapse
Affiliation(s)
- Mario Thevis
- German Sport University Cologne, Center for Preventive Doping Research/Institute of Biochemistry, Am Sportpark Muengersdorf 6, 50933 Cologne, Germany; European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany.
| | - Wilhelm Schänzer
- German Sport University Cologne, Center for Preventive Doping Research/Institute of Biochemistry, Am Sportpark Muengersdorf 6, 50933 Cologne, Germany
| |
Collapse
|
11
|
Rojas D, Dervilly-Pinel G, Cesbron N, Penot M, Sydor A, Prévost S, Le Bizec B. Selective androgen receptor modulators: comparative excretion study of bicalutamide in bovine urine and faeces. Drug Test Anal 2016; 9:1017-1025. [DOI: 10.1002/dta.2113] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2016] [Revised: 10/07/2016] [Accepted: 10/07/2016] [Indexed: 12/26/2022]
Affiliation(s)
- Dante Rojas
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes France
- Instituto Tecnología de Alimentos (ITA), Centro de Investigación de Agroindustria (CIA); Instituto Nacional de Tecnología Agropecuaria (INTA); CC77 Morón Argentina
| | - Gaud Dervilly-Pinel
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes France
| | - Nora Cesbron
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes France
| | - Mylène Penot
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes France
| | - Alexandre Sydor
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes France
| | - Stéphanie Prévost
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes France
| | - Bruno Le Bizec
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes France
| |
Collapse
|
12
|
Helmlin HJ, Mürner A, Steiner S, Kamber M, Weber C, Geyer H, Guddat S, Schänzer W, Thevis M. Detection of the diuretic hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-inflammatory drug (NSAID) tablet contamination. Forensic Sci Int 2016; 267:166-172. [DOI: 10.1016/j.forsciint.2016.08.029] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Revised: 08/07/2016] [Accepted: 08/19/2016] [Indexed: 11/24/2022]
|
13
|
Görgens C, Guddat S, Thomas A, Wachsmuth P, Orlovius AK, Sigmund G, Thevis M, Schänzer W. Simplifying and expanding analytical capabilities for various classes of doping agents by means of direct urine injection high performance liquid chromatography high resolution/high accuracy mass spectrometry. J Pharm Biomed Anal 2016; 131:482-496. [PMID: 27693991 DOI: 10.1016/j.jpba.2016.09.015] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 09/06/2016] [Accepted: 09/13/2016] [Indexed: 12/13/2022]
Abstract
So far, in sports drug testing compounds of different classes are processed and measured using different screening procedures. The constantly increasing number of samples in doping analysis, as well as the large number of substances with doping related, pharmacological effects require the development of even more powerful assays than those already employed in sports drug testing, indispensably with reduced sample preparation procedures. The analysis of native urine samples after direct injection provides a promising analytical approach, which thereby possesses a broad applicability to many different compounds and their metabolites, without a time-consuming sample preparation. In this study, a novel multi-target approach based on liquid chromatography and high resolution/high accuracy mass spectrometry is presented to screen for more than 200 analytes of various classes of doping agents far below the required detection limits in sports drug testing. Here, classic groups of drugs as diuretics, stimulants, β2-agonists, narcotics and anabolic androgenic steroids as well as various newer target compounds like hypoxia-inducible factor (HIF) stabilizers, selective androgen receptor modulators (SARMs), selective estrogen receptor modulators (SERMs), plasma volume expanders and other doping related compounds, listed in the 2016 WADA prohibited list were implemented. As a main achievement, growth hormone releasing peptides could be implemented, which chemically belong to the group of small peptides (<2kDa) and are commonly determined by laborious and time-consuming stand-alone assays. The assay was fully validated for qualitative purposes considering the parameters specificity, robustness (rRT: <2%), intra- (CV: 1.7-18.4 %) and inter-day precision (CV: 2.3-18.3%) at three concentration levels, linearity (R2>0.99), limit of detection (0.1-25ng/mL; 3'OH-stanozolol glucuronide: 50pg/mL; dextran/HES: 10μg/mL) and matrix effects.
Collapse
Affiliation(s)
- Christian Görgens
- Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany.
| | - Sven Guddat
- Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
| | - Andreas Thomas
- Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
| | - Philipp Wachsmuth
- Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
| | - Anne-Katrin Orlovius
- Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
| | - Gerd Sigmund
- Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
| | - Mario Thevis
- Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
| | - Wilhelm Schänzer
- Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
| |
Collapse
|
14
|
Hansson A, Knych H, Stanley S, Thevis M, Bondesson U, Hedeland M. Investigation of the selective androgen receptor modulators S1, S4 and S22 and their metabolites in equine plasma using high-resolution mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2016; 30:833-42. [PMID: 26969924 DOI: 10.1002/rcm.7512] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Revised: 01/13/2016] [Accepted: 01/16/2016] [Indexed: 05/21/2023]
Abstract
RATIONALE Selective androgen receptor modulators (SARMs) are prohibited in sports due to their performance enhancing ability. It is important to investigate the metabolism to determine appropriate targets for doping control. This is the first study where the equine metabolites of SARMs S1, S4 (Andarine) and S22 (Ostarine) have been studied in plasma. METHODS Each SARM was administered to three horses as an intravenous bolus dose and plasma samples were collected. The samples were pretreated with protein precipitation using cold acetonitrile before separation by liquid chromatography. The mass spectrometric analysis was performed using negative electrospray, quadrupole time-of-flight mass spectrometry operated in MS(E) mode and triple-quadrupole mass spectrometry operated in selected reaction monitoring mode. For the quantification of SARM S1, a deuterated analogue was used as internal standard. RESULTS The numbers of observed metabolites were eight, nine and four for the SARMs S1, S4 and S22, respectively. The major metabolite was formed by the same metabolic reactions for all three SARMs, namely amide hydrolysis, hydroxylation and sulfonation. The values of the determined maximum plasma concentrations were in the range of 97-170 ng/mL for SARM S1, 95-115 ng/mL for SARM S4 and 92-147 ng/mL for SARM S22 and the compounds could be detected for 96 h, 12 h and 18 h, respectively. CONCLUSIONS The maximum plasma concentration of SARMs S1, S4 and S22 was measured in the first sample (5 min) after administration and they were eliminated fast from plasma. The proposed targets to be used in equine doping control are the parent compounds for all three SARMs, but with the metabolite yielding the highest response as a complementary target. Copyright © 2016 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Annelie Hansson
- Division of Analytical Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala University, Box 574, SE-75123, Uppsala, Sweden
| | - Heather Knych
- K. L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA
- Department of Veterinary Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA
| | - Scott Stanley
- K. L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA
| | - Mario Thevis
- Institute of Biochemistry and Center for Preventive Doping Research, German Sport University, Cologne, Germany
| | - Ulf Bondesson
- Division of Analytical Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala University, Box 574, SE-75123, Uppsala, Sweden
- National Veterinary Institute (SVA), Department of Chemistry, Environment and Feed Hygiene, SE-75651, Uppsala, Sweden
| | - Mikael Hedeland
- Division of Analytical Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala University, Box 574, SE-75123, Uppsala, Sweden
- National Veterinary Institute (SVA), Department of Chemistry, Environment and Feed Hygiene, SE-75651, Uppsala, Sweden
| |
Collapse
|
15
|
Beucher L, Dervilly-Pinel G, Cesbron N, Penot M, Gicquiau A, Monteau F, Le Bizec B. Specific characterization of non-steroidal selective androgen peceptor modulators using supercritical fluid chromatography coupled to ion-mobility mass spectrometry: application to the detection of enobosarm in bovine urine. Drug Test Anal 2016; 9:179-187. [DOI: 10.1002/dta.1951] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Revised: 12/15/2015] [Accepted: 12/16/2015] [Indexed: 01/16/2023]
Affiliation(s)
- Laure Beucher
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes F-44307 France
| | - Gaud Dervilly-Pinel
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes F-44307 France
| | - Nora Cesbron
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes F-44307 France
| | - Mylène Penot
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes F-44307 France
| | - Audrey Gicquiau
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes F-44307 France
| | - Fabrice Monteau
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes F-44307 France
| | - Bruno Le Bizec
- LUNAM Université; Oniris, Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA); Nantes F-44307 France
| |
Collapse
|
16
|
Thevis M, Schänzer W. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2016; 30:635-651. [PMID: 26842585 DOI: 10.1002/rcm.7470] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Revised: 11/23/2015] [Accepted: 11/24/2015] [Indexed: 06/05/2023]
Abstract
RATIONALE A plethora of compounds potentially leading to drug candidates that affect skeletal muscle function and, more specifically, mitochondrial biogenesis, has been under (pre)clinical investigation for rare as well as more common diseases. Some of these compounds could be the object of misuse by athletes aiming at artificial and/or illicit and drug-facilitated performance enhancement, necessitating preventive and proactive anti-doping measures. METHODS Early warnings and the continuous retrieval and dissemination of information are crucial for sports drug testing laboratories as well as anti-doping authorities, as they assist in preparation of efficient doping control analytical strategies for potential future threats arising from new therapeutic developments. Scientific literature represents the main source of information, which yielded the herein discussed substances and therapeutic targets, which might become relevant for doping controls in the future. Where available, mass spectrometric data are presented, supporting the development of analytical strategies and characterization of compounds possibly identified in human sports drug testing samples. RESULTS & CONCLUSIONS Focusing on skeletal muscle and mitochondrial biogenesis, numerous substances exhibiting agonistic or antagonistic actions on different cellular 'control centers' resulting in increased skeletal muscle mass, enhanced performance (as determined with laboratory animal models), and/or elevated amounts of mitochondria have been described. Substances of interest include agonists for REV-ERBα (e.g. SR9009, SR9011, SR10067, GSK4112), sirtuin 1 (e.g. SRT1720, SRT2104), adenosine monophosphate-activated protein kinase (AMPK, e.g. AICAR), peroxisome proliferator-activated receptor (PPAR)δ (e.g. GW1516, GW0742, L165041), and inhibitory/antagonistic agents targeting the methionine-folate cycle (MOTS-c), the general control non-derepressible 5 (GCN5) acetyl transferase (e.g. CPTH2, MB-3), myostatin (e.g. MYO-029), the myostatin receptor (bimagrumab), and myostatin receptor ligands (e.g. sotatercept, ACE-031). In addition, potentially relevant drug targets were identified, e.g. with the sarcoplasmic transmembrane peptide myoregulin and the nuclear receptor corepressor 1 (NCOR-1). The antagonism of these has shown to result in substantially enhanced physical performance in animals, necessitating the monitoring of strategies such as RNA interference regarding these substances. Most drug candidates are of lower molecular mass and comprise non-natural compositions, facts which suggest approaches for their qualitative identification in doping control samples by mass spectrometry. Electrospray ionization/collision-induced dissociation mass spectra of representatives of the aforementioned substances and selected in vitro derived phase-I metabolites support this assumption, and test methods for a subset of these have been recently established. Expanding the knowledge on analytical data will further facilitate the identification of such analytes and related compounds in confiscated material as well as sports drug testing specimens.
Collapse
Affiliation(s)
- Mario Thevis
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Muengersdorf 6, 50933, Cologne, Germany
- European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany
| | - Wilhelm Schänzer
- Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Muengersdorf 6, 50933, Cologne, Germany
- European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany
| |
Collapse
|
17
|
Geldof L, Pozo OJ, Lootens L, Morthier W, Van Eenoo P, Deventer K. In vitro metabolism study of a black market product containing SARM LGD-4033. Drug Test Anal 2016; 9:168-178. [PMID: 26767942 DOI: 10.1002/dta.1930] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Revised: 11/05/2015] [Accepted: 11/15/2015] [Indexed: 01/02/2023]
Abstract
Anabolic agents are often used by athletes to enhance their performance. However, use of steroids leads to considerable side effects. Non-steroidal selective androgen receptor modulators (SARMs) are a novel class of substances that have not been approved so far but seem to have a more favourable anabolic/androgenic ratio than steroids and produce fewer side effects. Therefore the use of SARMs has been prohibited since 2008 by the World Anti-Doping Agency (WADA). Several of these SARMs have been detected on the black market. Metabolism studies are essential to identify the best urinary markers to ensure effective control of emerging substances by doping control laboratories. As black market products often contain non-pharmaceutical-grade substances, alternatives for human excretion studies are needed to elucidate the metabolism. A black market product labelled to contain the SARM LGD-4033 was purchased over the Internet. Purity verification of the black market product led to the detection of LGD-4033, without other contaminants. Human liver microsomes and S9 liver fractions were used to perform phase I and phase II (glucuronidation) metabolism studies. The samples of the in vitro metabolism studies were analyzed by gas chromatography-(tandem) mass spectrometry (GC-MS(/MS)), liquid chromatography-high resolution-tandem mass spectrometry (LC-(HR)MS/MS). LC-HRMS product ion scans allowed to identify typical fragment ions for the parent compound and to further determine metabolite structures. In total five metabolites were detected, all modified in the pyrrolidine ring of LGD-4033. The metabolic modifications ranged from hydroxylation combined with keto-formation (M1) or cleavage of the pyrrolidine ring (M2), hydroxylation and methylation (M3/M4) and dihydroxylation (M5). The parent compound and M2 were also detected as glucuronide-conjugates. Copyright © 2016 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Lore Geldof
- Doping Control Laboratory (DoCoLab), Ghent University (UGent), Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30B, Zwijnaarde, B-9052, Belgium
| | - Oscar J Pozo
- IMIM - Hospital del Mar Medical Research Institute, Bioanalysis Research Group, Doctor Aiguader 88, 08003, Barcelona, Spain
| | - Leen Lootens
- Doping Control Laboratory (DoCoLab), Ghent University (UGent), Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30B, Zwijnaarde, B-9052, Belgium
| | - Wouter Morthier
- Doping Control Laboratory (DoCoLab), Ghent University (UGent), Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30B, Zwijnaarde, B-9052, Belgium
| | - Peter Van Eenoo
- Doping Control Laboratory (DoCoLab), Ghent University (UGent), Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30B, Zwijnaarde, B-9052, Belgium
| | - Koen Deventer
- Doping Control Laboratory (DoCoLab), Ghent University (UGent), Department of Clinical Chemistry, Microbiology and Immunology, Technologiepark 30B, Zwijnaarde, B-9052, Belgium
| |
Collapse
|
18
|
|
19
|
Cawley AT, Smart C, Greer C, Liu Lau M, Keledjian J. Detection of the selective androgen receptor modulator andarine (S-4) in a routine equine blood doping control sample. Drug Test Anal 2015; 8:257-61. [DOI: 10.1002/dta.1867] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Revised: 08/05/2015] [Accepted: 08/16/2015] [Indexed: 11/10/2022]
Affiliation(s)
- Adam T. Cawley
- Australian Racing Forensic Laboratory; Racing NSW; Randwick NSW Australia
| | - Corrine Smart
- Australian Racing Forensic Laboratory; Racing NSW; Randwick NSW Australia
| | - Candace Greer
- Australian Racing Forensic Laboratory; Racing NSW; Randwick NSW Australia
| | - Marcus Liu Lau
- Australian Racing Forensic Laboratory; Racing NSW; Randwick NSW Australia
| | - John Keledjian
- Australian Racing Forensic Laboratory; Racing NSW; Randwick NSW Australia
| |
Collapse
|
20
|
Thevis M, Geyer H, Thomas A, Tretzel L, Bailloux I, Buisson C, Lasne F, Schaefer MS, Kienbaum P, Mueller-Stoever I, Schänzer W. Formation of the diuretic chlorazanil from the antimalarial drug proguanil--implications for sports drug testing. J Pharm Biomed Anal 2015. [PMID: 26226108 DOI: 10.1016/j.jpba.2015.07.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Chlorazanil (Ordipan, N-(4-chlorophenyl)-1,3,5-triazine-2,4-diamine) is a diuretic agent and as such prohibited in sport according to the regulations of the World Anti-Doping Agency (WADA). Despite its introduction into clinical practice in the late 1950s, the worldwide very first two adverse analytical findings were registered only in 2014, being motive for an in-depth investigation of these cases. Both individuals denied the intake of the drug; however, the athletes did declare the use of the antimalarial prophylactic agent proguanil due to temporary residences in African countries. A structural similarity between chlorazanil and proguanil is given but no direct metabolic relation has been reported in the scientific literature. Moreover, chlorazanil has not been confirmed as a drug impurity of proguanil. Proguanil however is metabolized in humans to N-(4-chlorophenyl)-biguanide, which represents a chemical precursor in the synthesis of chlorazanil. In the presence of formic acid, formaldehyde, or formic acid esters, N-(4-chlorophenyl)-biguanide converts to chlorazanil. In order to probe for potential sources of the chlorazanil detected in the doping control samples, drug formulations containing proguanil and urine samples of individuals using proguanil as antimalarial drug were subjected to liquid chromatography-high resolution/high accuracy mass spectrometry. In addition, in vitro simulations with 4-chlorophenyl-biguanide and respective reactants were conducted in urine and resulting specimens analyzed for the presence of chlorazanil. While no chlorazanil was found in drug formulations, the urine samples of 2 out of 4 proguanil users returned findings for chlorazanil at low ng/mL levels, similar to the adverse analytical findings in the doping control samples. Further, in the presence of formaldehyde, formic acid and related esters, 4-chlorophenyl-biguanide was found to produce chlorazanil in human urine, suggesting that the detection of the obsolete diuretic agent was indeed the result of artefact formation and not of the illicit use of a prohibited substance.
Collapse
Affiliation(s)
- Mario Thevis
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany; European Monitoring Center for Emerging Doping Agents, Cologne/Bonn, Germany.
| | - Hans Geyer
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
| | - Andreas Thomas
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
| | - Laura Tretzel
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
| | - Isabelle Bailloux
- Agence Française de Lutte contre le Dopage (AFLD), 143 avenue Roger Salengro, 92290 Châtenay-Malabry, France
| | - Corinne Buisson
- Agence Française de Lutte contre le Dopage (AFLD), 143 avenue Roger Salengro, 92290 Châtenay-Malabry, France
| | - Francoise Lasne
- Agence Française de Lutte contre le Dopage (AFLD), 143 avenue Roger Salengro, 92290 Châtenay-Malabry, France
| | - Maximilian S Schaefer
- Department of Anaesthesiology, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany
| | - Peter Kienbaum
- Department of Anaesthesiology, University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany
| | - Irmela Mueller-Stoever
- Tropical Medicine Unit, University Hospital for Gastroenterology, Hepatology and Infectious Diseases, Heinrich-Heine-University Duesseldorf, Germany
| | - Wilhelm Schänzer
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany
| |
Collapse
|
21
|
Domínguez-Romero JC, García-Reyes JF, Lara-Ortega FJ, Molina-Díaz A. Screening and confirmation capabilities of liquid chromatography-time-of-flight mass spectrometry for the determination of 200 multiclass sport drugs in urine. Talanta 2015; 134:74-88. [DOI: 10.1016/j.talanta.2014.10.050] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2014] [Revised: 10/15/2014] [Accepted: 10/24/2014] [Indexed: 12/25/2022]
|
22
|
Knoop A, Krug O, Vincenti M, Schänzer W, Thevis M. In vitro metabolism studies on the selective androgen receptor modulator (SARM) LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry. EUROPEAN JOURNAL OF MASS SPECTROMETRY (CHICHESTER, ENGLAND) 2015; 21:27-36. [PMID: 25906032 DOI: 10.1255/ejms.1328] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
LG121071 is a member of the tetrahydroquinolinone-based class of selective androgen receptor modulator (SARM) drug candidates. These nonsteroidal compounds are supposed to act as full anabolic agents with reduced androgenic properties. As SARMs provide an alternative to anabolic androgenic steroids, they represent an emerging class of potential doping substances abused by athletes for illicit performance enhancement. According to the World Anti-Doping Agency's regulations, SARMs are banned substances and part of the Prohibited List since 2008. In consideration of the increasing number of adverse analytical findings in doping controls caused by SARMs abuse, potential drug candidates such as LG121071 have been proactively investigated to enable a timely integration into routine testing procedures even though clinical trials are not yet complete. In the present approach, the collision-induced dissociation (CID) of LG121071 was characterized by means of electrospray ionization-high resolution/high accuracy mass spectrometry, MS(n), and isotope labeling experiments. Interestingly, the even-electron precursor ion [M + H](+) at m/z 297 was found to produce a radical cation at m/z 268 under CID conditions, violating the even-electron rule that commonly applies. For doping control purposes, metabolites were generated in vitro and a detection method for urine samples based on liquid chromatography-tandem mass spectrometry was established. The overall metabolic conversion of LG121071 was modest, yielding primarily mono-, bis- and trishydroxylated species. Notable, however, was the identification of a glucuronic acid conjugate of the intact drug, attributed to an N-glucuronide structure. The sample preparation procedure included the enzymatic hydrolysis of glucuronides prior to liquid-liquid extraction, allowing intact LG121071 to be measured, as well as the corresponding phase-I metabolites. The method was characterized concerning inter alia lower limit of detection (0.5 ng mL(-1) in urine), recovery (40%), and intra-/interday precision (2.3% to 11.7%) to assess its fitness for purpose. Prospectively, the assay can serve as detection method for LG121071 in drug testing and/or doping controls.
Collapse
Affiliation(s)
- Andre Knoop
- Institute for Biochemistry- Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany..
| | - Oliver Krug
- Institute for Biochemistry- Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany. European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany.
| | - Marco Vincenti
- Dipartimento di Chimica, Università degli Studi di Torino, via P. Giuria 7, 10125 Turin, Italy.
| | - Wilhelm Schänzer
- Institute for Biochemistry- Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany..
| | - Mario Thevis
- Institute for Biochemistry- Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany. European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany.
| |
Collapse
|
23
|
Mazzarino M, de la Torre X, Botrè F. A liquid chromatography-mass spectrometry method based on class characteristic fragmentation pathways to detect the class of indole-derivative synthetic cannabinoids in biological samples. Anal Chim Acta 2014; 837:70-82. [PMID: 25000860 DOI: 10.1016/j.aca.2014.06.003] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2014] [Revised: 05/12/2014] [Accepted: 06/03/2014] [Indexed: 12/22/2022]
Abstract
This article describes a liquid chromatographic/tandem mass spectrometric method, based on the use of precursor ion scan as the acquisition mode, specifically developed to detect indole-derived cannabinoids (phenylacetylindoles, naphthoylindoles and benzoylindoles) in biological fluids (saliva, urine and blood). The method is designed to recognize one or more common "structural markers", corresponding to mass spectral fragments originating from the specific portion of the molecular structure that is common to the aminoalkylindole analogues and that is fundamental for their pharmacological classification. As such, the method is also suitable for detecting unknown substances, provided they contain the targeted portion of the molecular structure. The pre-treatment procedure consists in a liquid/liquid extraction step carried out at neutral pH: this is the only pretreatment in the case of analyses carried out in saliva, while it follows an enzymatic hydrolysis procedure in the case of urine samples, or a protein precipitation step in the case of blood samples. The chromatographic separation is achieved using an octadecyl reverse-phase 5 μm fused-core particle column; while the mass spectrometric detection is carried out by a triple-quadrupole instrument in positive electrospray ionization and precursor ion scan as acquisition mode, selecting, as mass spectral fragments, the indole (m/z 144), the carbonylnaphthalenyl (m/z 155) and the naphthalenyl (m/z 127) moieties. Once developed and optimized, the analytical procedure was validated in term of sensitivity (lower limits of detection in the range of 0.1-0.5 ng mL(-1)), specificity (no interference was detected at the retention times of the analytes under investigation), recovery (higher than 65% with a satisfactory repeatability: CV% lower than 10), matrix effect (lower than 30% for all the biological specimens tested), repeatability of the retention times (CV% lower than 0.1), robustness, and carry over (the positive reference samples at a concentration 20 times the LLOD value did not affect the blank samples). The suitability of the proposed procedure, both as a targeted and an untargeted approach, was verified by analyzing samples containing synthetic cannabinoids and/or their metabolites and samples obtained from the incubation of synthetic cannabinoids with human liver microsomes.
Collapse
Affiliation(s)
- Monica Mazzarino
- Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti 1, 00197, Rome, Italy
| | - Xavier de la Torre
- Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti 1, 00197, Rome, Italy
| | - Francesco Botrè
- Laboratorio Antidoping, Federazione Medico Sportiva Italiana, Largo Giulio Onesti 1, 00197, Rome, Italy; Dipartimento di Medicina Sperimentale, "Sapienza" Università di Roma, Viale Regina Elena 324, 00161, Rome, Italy.
| |
Collapse
|
24
|
Geyer H, Schänzer W, Thevis M. Anabolic agents: recent strategies for their detection and protection from inadvertent doping. Br J Sports Med 2014; 48:820-6. [PMID: 24632537 PMCID: PMC4033149 DOI: 10.1136/bjsports-2014-093526] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
According to the World Anti-Doping Agency (WADA) Prohibited List, anabolic agents consist of exogenous anabolic androgenic steroids (AAS), endogenous AAS and other anabolic agents such as clenbuterol and selective androgen receptor modulators (SARMs). Currently employed strategies for their improved detection include the prolongation of the detection windows for exogenous AAS, non-targeted and indirect analytical approaches for the detection of modified steroids (designer steroids), the athlete's biological passport and isotope ratio mass spectrometry for the detection of the misuse of endogenous AAS, as well as preventive doping research for the detection of SARMs. The recent use of these strategies led to 4-80-fold increases of adverse analytical findings for exogenous AAS, to the detection of the misuse of new designer steroids, to adverse analytical findings of different endogenous AAS and to the first adverse analytical findings of SARMs. The strategies of the antidoping research are not only focused on the development of methods to catch the cheating athlete but also to protect the clean athlete from inadvertent doping. Within the past few years several sources of inadvertent doping with anabolic agents have been identified. Among these are nutritional supplements adulterated with AAS, meat products contaminated with clenbuterol, mycotoxin (zearalenone) contamination leading to zeranol findings, and natural products containing endogenous AAS. The protection strategy consists of further investigations in case of reasonable suspicion of inadvertent doping, publication of the results, education of athletes and development of methods to differentiate between intentional and unintentional doping.
Collapse
Affiliation(s)
- Hans Geyer
- Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, , Cologne, Germany
| | | | | |
Collapse
|
25
|
Botrè F. Mass spectrometry and illicit drug testing: analytical challenges of the anti-doping laboratories. Expert Rev Proteomics 2014; 5:535-9. [DOI: 10.1586/14789450.5.4.535] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
26
|
Mass spectrometric characterization of glucuronides formed by a new concept, combining Cunninghamella elegans with TEMPO. J Pharm Biomed Anal 2013; 84:278-84. [DOI: 10.1016/j.jpba.2013.06.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2013] [Revised: 06/05/2013] [Accepted: 06/06/2013] [Indexed: 01/21/2023]
|
27
|
de Rijke E, Essers ML, Rijk JC, Thevis M, Bovee TF, van Ginkel LA, Sterk SS. Selective androgen receptor modulators:in vitroandin vivometabolism and analysis. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2013; 30:1517-26. [DOI: 10.1080/19440049.2013.810346] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
28
|
Rydevik A, Thevis M, Krug O, Bondesson U, Hedeland M. The fungusCunninghamella eleganscan produce human and equine metabolites of selective androgen receptor modulators (SARMs). Xenobiotica 2012; 43:409-20. [DOI: 10.3109/00498254.2012.729102] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
29
|
Thevis M, Schänzer W. Illicit organogenesis: Methods and substances of doping and manipulation. Organogenesis 2012; 4:264-71. [PMID: 19337407 DOI: 10.4161/org.4.4.7286] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2008] [Accepted: 10/29/2008] [Indexed: 01/12/2023] Open
Abstract
Doping and manipulation are undesirable companions of professional and amateur sport. Numerous adverse analytical findings as well as confessions of athletes have demonstrated the variety of doping agents and methods as well as the inventiveness of cheating sportsmen. Besides 'conventional' misuse of drugs such as erythropoietin and insulins, experts fear that therapeutics that are currently undergoing clinical trials might be part of current or future doping regimens, which aim for an increased functionality and performance or organs and tissues. Emerging drugs such as selective androgen receptor modulators (SARMs), hypoxia-inducible factor (HIF) complex stabilizers or modulators of muscle fiber calcium channels are considered relevant for current and future doping controls due to their high potential for misuse in sports.
Collapse
Affiliation(s)
- Mario Thevis
- Center for Preventive Doping Research; Institute of Biochemistry; German Sport University Cologne; Cologne Germany
| | | |
Collapse
|
30
|
Krug O, Thomas A, Beuck S, Schenk I, Machnik M, Schänzer W, Bondesson U, Hedeland M, Thevis M. Characterization of In Vitro Synthesized Equine Metabolites of the Selective Androgen Receptor Modulators S24 and S4. J Equine Vet Sci 2012. [DOI: 10.1016/j.jevs.2012.01.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Guddat S, Solymos E, Orlovius A, Thomas A, Sigmund G, Geyer H, Thevis M, Schänzer W. High-throughput screening for various classes of doping agents using a new ‘dilute-and-shoot’ liquid chromatography-tandem mass spectrometry multi-target approach. Drug Test Anal 2011; 3:836-50. [DOI: 10.1002/dta.372] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2011] [Revised: 08/31/2011] [Accepted: 09/12/2011] [Indexed: 11/11/2022]
Affiliation(s)
- S. Guddat
- Institute of Biochemistry and Center for Preventive Doping Research; German Sport University Cologne
| | - E. Solymos
- Eötvös Loránd University; Joint Research and Training Laboratory on Separation Techniques; Budapest; Hungary
| | | | - A. Thomas
- Institute of Biochemistry and Center for Preventive Doping Research; German Sport University Cologne
| | - G. Sigmund
- Institute of Biochemistry and Center for Preventive Doping Research; German Sport University Cologne
| | - H. Geyer
- Institute of Biochemistry and Center for Preventive Doping Research; German Sport University Cologne
| | - M. Thevis
- Institute of Biochemistry and Center for Preventive Doping Research; German Sport University Cologne
| | - W. Schänzer
- Institute of Biochemistry and Center for Preventive Doping Research; German Sport University Cologne
| |
Collapse
|
32
|
Grata E, Perrenoud L, Saugy M, Baume N. SARM-S4 and metabolites detection in sports drug testing: A case report. Forensic Sci Int 2011; 213:104-8. [DOI: 10.1016/j.forsciint.2011.07.014] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2011] [Revised: 06/30/2011] [Accepted: 07/06/2011] [Indexed: 10/17/2022]
|
33
|
Sukhanova II, Dikunets MA, Viryus ED, Rodchenkov GM. Magnetic separation as a new method for the extraction of small molecules from biological fluids of humans. JOURNAL OF ANALYTICAL CHEMISTRY 2011. [DOI: 10.1134/s1061934811090164] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
34
|
Thevis M, Thomas A, Möller I, Geyer H, Dalton JT, Schänzer W. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2011; 25:2187-95. [PMID: 21710598 DOI: 10.1002/rcm.5100] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Drugs that promote anabolic processes with limited undesirable effects are of considerable therapeutic interest; some notable examples include those for the treatment of cancer cachexia and muscle-wasting diseases. Anabolic properties are not only therapeutically beneficial to critically ill and debilitated patients, but are also desirable to athletes seeking artificial enhancements in endurance, strength and accelerated recovery. The use of anabolic agents in the clinical setting is being reconsidered with the emergence of a new class of drugs referred to as SARMs (selective androgen receptor modulators). SARMs have the potential to complement or even replace anabolic androgenic steroidal use with the benefit of a reduction of the undesirable side effects associated with steroid administration alone. Arylpropionamide-based SARMs such as andarine (S-4) and S-22 have shown promising therapeutic properties and have attracted the interest of elite and amateur athletes despite the absence of clinical approval, and evidence for trafficking and misuse in sport has been obtained by doping control authorities. In this communication, the elucidation of urinary metabolites of the SARM drug candidate S-22 is compared with earlier in vitro metabolism studies. Following oral administration of illicit S-22, urine samples were collected after 62 and 135 h and analyzed for the active drug and its major metabolic products. Liquid chromatography interfaced with high-resolution/high-accuracy (tandem) mass spectrometry was used to identify and/or confirm the predicted target analytes for sports drug testing purposes. S-22 was detected in both specimens accompanied by its glucuronic acid conjugate. This was the B-ring hydroxylated derivative of S-22 plus the corresponding glucuronide (with the phase-II metabolites being the more abundant analytes). In addition, the samples collected 62 h post-administration also contained the phase-I metabolite hydroxylated at the methyl residue (C-20) and the B-ring depleted degradation product ('dephenylated' S-22) together with the corresponding carboxy analog that was previously reported for canine metabolism. The obtained data supports future efforts to effectively screen for and confirm the misuse of the non-approved S-22 drug candidate in doping controls.
Collapse
Affiliation(s)
- Mario Thevis
- Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
| | | | | | | | | | | |
Collapse
|
35
|
Thevis M, Geyer H, Kamber M, Schänzer W. Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product. Drug Test Anal 2011; 1:387-92. [PMID: 20355219 DOI: 10.1002/dta.91] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Non-steroidal and tissue-selective anabolic agents such as selective androgen receptor modulators (SARMs) represent a promising class of therapeutics for the treatment of various diseases such as sarcopenia or cancer cachexia. Advanced compounds of SARMs are based on an arylpropionamide-derived structure and leading drug candidates have successfully completed phase-II-clinical trials. Although none of these therapeutics have been approved, their performance-enhancing qualities and the black-market availability of these products makes them a viable target for misuse in the athletic community. In 2008, SARMs were added to the Prohibited List established by the World Anti-Doping Agency (WADA). That SARMs are the subject of misuse even without clinical approval was proved for the first time by the detection of the drug candidate Andarine (also referred to as S-4, S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide), advertised, sold and supplied via the Internet. The oily liquids, declared as green tea extracts and face moisturizer, were assayed using state-of-the-art analytical procedures and S-4 was found at concentrations of approximately 150 mg/mL. The authenticity of the product was demonstrated in comparison to reference material by liquid chromatography, high resolution/high accuracy (tandem) mass spectrometry using positive and negative electrospray ionization, and comparison to reference material. Moreover, an impurity resulting from poor product purification was detected, accounting for approximately 10% of S-4. This consisted of 2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-3-(4-nitro-3-trifluoromethyl-phenylamino)-propionamide. The ease of purchasing non-approved drug candidates that could potentially increase athletic performance demonstrates the need to operate proactively in the continued fight against doping. The early inclusion of emerging drugs into routine sports drug testing procedures is a key element of preventive doping research, limiting the options for cheating athletes who aim to undermine the doping control system.
Collapse
Affiliation(s)
- Mario Thevis
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany.
| | | | | | | |
Collapse
|
36
|
Thevis M, Thomas A, Schänzer W. Current role of LC-MS(/MS) in doping control. Anal Bioanal Chem 2011; 401:405-20. [DOI: 10.1007/s00216-011-4859-9] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2011] [Revised: 02/24/2011] [Accepted: 02/26/2011] [Indexed: 11/30/2022]
|
37
|
Gerace E, Salomone A, Fasano F, Costa R, Boschi D, Di Stilo A, Vincenti M. Validation of a GC/MS method for the detection of two quinolinone-derived selective androgen receptor modulators in doping control analysis. Anal Bioanal Chem 2010; 400:137-44. [DOI: 10.1007/s00216-010-4569-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2010] [Revised: 11/25/2010] [Accepted: 11/29/2010] [Indexed: 01/03/2023]
|
38
|
Kohler M, Thomas A, Geyer H, Petrou M, Schänzer W, Thevis M. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the cologne doping control laboratory 2009. Drug Test Anal 2010; 2:533-7. [DOI: 10.1002/dta.186] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2010] [Revised: 08/16/2010] [Accepted: 08/18/2010] [Indexed: 12/11/2022]
|
39
|
Thevis M, Gerace E, Thomas A, Beuck S, Geyer H, Schlörer N, Kearbey JD, Dalton JT, Schänzer W. Characterization of in vitro generated metabolites of the selective androgen receptor modulators S-22 and S-23 and in vivo comparison to post-administration canine urine specimens. Drug Test Anal 2010; 2:589-98. [DOI: 10.1002/dta.211] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2010] [Revised: 08/27/2010] [Accepted: 09/12/2010] [Indexed: 12/11/2022]
|
40
|
Thevis M, Thomas A, Fusshöller G, Beuck S, Geyer H, Schänzer W. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator andarine (S-4) for routine doping control purposes. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2010; 24:2245-54. [PMID: 20623476 DOI: 10.1002/rcm.4637] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Selective androgen receptor modulators (SARMs) are potent anabolic agents with tissue-selective properties. Due to their potential misuse in elite sport, the World Anti-Doping Agency (WADA) has prohibited SARMs since 2008, and although no representative drug candidate has yet received full clinical approval, recent findings of SARMs illegally sold via the internet have further supported the need to efficiently test for these compounds in doping controls. In the present communication, the mass spectrometric characterization of urinary metabolites of the SARM Andarine (also referred to as S-4) compared with earlier in vitro and animal studies is reported. Liquid chromatography interfaced to high-resolution/high-accuracy (tandem) mass spectrometry was used to identify phase I and II metabolites, confirming the predicted target analytes for sports drug testing purposes including the glucuronic acid conjugates of the active drug, its monohydroxylated and/or deacetylated product, the hydrolysis product resulting from the removal of the compound's B-ring, as well as the sulfate of the monohydroxylated and the deacetylated phase I metabolite. The obtained data will support future efforts to effectively screen for and confirm the misuse of the non-approved drug candidate Andarine.
Collapse
Affiliation(s)
- Mario Thevis
- Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany.
| | | | | | | | | | | |
Collapse
|
41
|
Identification of anabolic steroids and derivatives using bioassay-guided fractionation, UHPLC/TOFMS analysis and accurate mass database searching. Anal Chim Acta 2010; 664:77-88. [DOI: 10.1016/j.aca.2010.01.065] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2009] [Revised: 01/27/2010] [Accepted: 01/31/2010] [Indexed: 01/31/2023]
|
42
|
Bovee TFH, Thevis M, Hamers ARM, Peijnenburg AACM, Nielen MWF, Schoonen WGEJ. SERMs and SARMs: detection of their activities with yeast based bioassays. J Steroid Biochem Mol Biol 2010; 118:85-92. [PMID: 19883760 DOI: 10.1016/j.jsbmb.2009.10.007] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2009] [Revised: 10/21/2009] [Accepted: 10/22/2009] [Indexed: 12/21/2022]
Abstract
Selective estrogen receptor modulators (SERMs) and selective androgen receptor modulators (SARMs) are compounds that activate their cognate receptor in particular target tissues without affecting other organs. Many of these compounds will find their use in therapeutic treatments. However, they also will have a high potential for misuse in veterinary practice and the sporting world. Here we demonstrate that yeast estrogen and androgen bioassays can be used to detect SERMs and SARMs, and are also useful screening tools to investigate their mode of action. Six steroidal 11beta-substituents of E2 (SERMs) and some arylpropionamide- and quinoline-based SARMs were tested. In addition, 7 compounds previously tested on AR agonism and determined as inactive in the yeast androgen bioassay, while QSAR modelling revealed strong binding to the human androgen receptor, are now shown to act as AR antagonists.
Collapse
Affiliation(s)
- Toine F H Bovee
- RIKILT-Institute of Food Safety, Department of Safety & Health, Wageningen, The Netherlands.
| | | | | | | | | | | |
Collapse
|
43
|
Zilbermint MF, Dobs AS. Nonsteroidal selective androgen receptor modulator Ostarine™in cancer cachexia. Future Oncol 2009; 5:1211-20. [DOI: 10.2217/fon.09.106] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
|
44
|
Peters RJB, van Engelen MC, Touber ME, Georgakopoulus C, Nielen MWF. Searching for in silico predicted metabolites and designer modifications of (cortico)steroids in urine by high-resolution liquid chromatography/time-of-flight mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2009; 23:2329-2337. [PMID: 19575408 DOI: 10.1002/rcm.4153] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Glucocorticosteroids are a restricted class of substances and appear on the 'in-competition' prohibited list of the World Anti-Doping Agency (WADA). Analysis of glucocorticosteroids is complicated since they show significant phase 1 and 2 metabolism in the human body and are excreted into urine in concentrations in the microg/L range. Full scan, high-resolution time-of-flight mass spectrometry analysis generates information on all ionisable components in urine, including known and unknown metabolites of steroids and even designer modifications of anabolic steroids. However, evaluation of the data obtained can be difficult and time-consuming because of the need to differentiate between endogenous components and compounds of interest. MetaboLynx, a spectral and chromatographic search program, was modified for the determination of in silico predicted metabolites of glucocorticosteroids and designer modifications of anabolic steroids in human urine. Spiked urine samples were successfully screened for known components in a targeted approach and for unknown species in a non-targeted approach using data filtering to limit potential false-positives. A simplified combined approach of targeted and untargeted screening was used for the detection of metabolites and designer modifications of existing compounds. This approach proved successful and showed its strength in the detection of tetrahydrogestrinone (THG), a designer modification of gestrinone. THG was positively detected in a spiked urine sample and correctly identified as a twofold hydrogenation of gestrinone. The developed screening method can easily be adapted to specific needs and it is envisaged that a similar approach would be amendable to the discovery of metabolites or designer modifications of other compounds of interest.
Collapse
Affiliation(s)
- Ruud J B Peters
- RIKILT - Institute of Food Safety, P.O. Box 230, 6700 AE Wageningen, The Netherlands.
| | | | | | | | | |
Collapse
|
45
|
Abstract
The continuing desire to analyze complex biological samples with the minimum number of steps places high demands on increasing speed, dynamic signal range, quantitative capability and the facility with which the mass spectrometers can interface with chromatographic separation methods. Reliable identification of metabolites in complex mixtures requires robust mass spectrometers with high resolving power, mass accuracy, sensitivity and dynamic range, while tandem MS is an invaluable tool for further structural characterization. This review begins with a discussion of the key properties of the Orbitrap™ mass analyzer: mass accuracy, resolution, fidelity of isotope pattern abundancies and dynamic range. The main objective is to provide an overview of Orbitrap applications in the field of bioanalysis. Specific areas of drug metabolism, doping control and food contaminants are discussed in detail illustrating the performance and versatility of the Orbitrap mass analyzer.
Collapse
|
46
|
Thevis M, Thomas A, Kohler M, Beuck S, Schänzer W. Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. JOURNAL OF MASS SPECTROMETRY : JMS 2009; 44:442-460. [PMID: 19373874 DOI: 10.1002/jms.1584] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
The number of compounds and doping methods in sports is in a state of constant flux. In addition to 'traditional' doping agents, such as anabolic androgenic steroids or erythropoietin, new therapeutics and emerging drugs have considerable potential for misuse in elite sport. Such compounds are commonly based on new chemical structures, and the mechanisms underlying their modes of action represent new therapeutic approaches arising from recent advances in medical research; therefore, sports drug testing procedures need to be continuously modified and complementary methods developed, preferably based on mass spectrometry, to enable comprehensive doping controls. This tutorial not only discusses emerging drugs that can be categorized as anabolic agents (selective androgen receptor modulators, SARMs), gene doping [hypoxia-inducible factor stabilizers, peroxisome-proliferator-activated receptor (PPAR)delta-agonists] and erythropoietin-mimetics (Hematide) but also compounds with potentially performance-enhancing properties that are not classified in the current list of the World Anti-Doping Agency. Compounds such as ryanodine-calstabin-complex modulators (benzothiazepines) are included, their mass spectrometric properties discussed, and current approaches in sports drug testing outlined.
Collapse
Affiliation(s)
- Mario Thevis
- Center for Preventive Doping Research-Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany.
| | | | | | | | | |
Collapse
|
47
|
Thevis M, Beuck S, Thomas A, Kortner B, Kohler M, Rodchenkov G, Schänzer W. Doping control analysis of emerging drugs in human plasma - identification of GW501516, S-107, JTV-519, and S-40503. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2009; 23:1139-1146. [PMID: 19280612 DOI: 10.1002/rcm.3987] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
An important aspect of preventive doping research is the rapid implementation of tests for emerging drugs with potential for misuse into routine doping control assays. New therapeutics of different classes such as PPARdelta-agonists (e.g. GW501516), ryanodine-calstabin-complex stabilizers (e.g. S-107 and JTV-519), and selective androgen receptor modulators (SARMs, e.g. S-40503) are currently used for the treatment of particular medical conditions such as metabolic syndrome, cardiac arrhythmia, debilitating diseases and osteoporosis, respectively. Due to their being at an early stage of clinical trials and the limited availability of data on the metabolism and possible renal elimination of the active drugs, the development of protocols for doping control analyses of plasma specimens could be an option for the detection of the circulating agents. The mass spectrometric fragmentation of four emerging drug candidates (GW501516, S-107, JTV-519, and S-40503) was elucidated by positive electrospray ionization and collision-induced dissociation using a high resolution/high accuracy mass spectrometer. A screening and confirmation procedure was established based on liquid chromatography/tandem mass spectrometry requiring a volume of 100 microL of plasma. Proteins were precipitated using acetonitrile, the specimens were centrifuged and the supernatant analyzed using a triple-quadrupole mass spectrometer employing multiple reaction monitoring of diagnostic ion transitions. The method was validated with regard to specificity, limits of detection (0.4-8.3 ng/mL), recoveries (72-98%), intraday and interday precisions (12-21%), and ion suppression/enhancement effects.
Collapse
Affiliation(s)
- Mario Thevis
- Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany.
| | | | | | | | | | | | | |
Collapse
|
48
|
Thevis M, Beuck S, Thomas A, Kohler M, Schlörer N, Vajiala I, Schänzer W. Screening for the calstabin-ryanodine receptor complex stabilizers JTV-519 and S-107 in doping control analysis. Drug Test Anal 2009; 1:32-42. [DOI: 10.1002/dta.13] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
49
|
Thevis M, Schänzer W. Synthetic anabolic agents: steroids and nonsteroidal selective androgen receptor modulators. Handb Exp Pharmacol 2009:99-126. [PMID: 20020362 DOI: 10.1007/978-3-540-79088-4_5] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The central role of testosterone in the development of male characteristics, as well as its beneficial effects on physical performance and muscle growth, has led to the search for synthetic alternatives with improved pharmacological profiles. Hundreds of steroidal analogs have been prepared with a superior oral bioavailability, which should also possess reduced undesirable effects. However, only a few entered the pharmaceutical market due to severe toxicological incidences that were mainly attributed to the lack of tissue selectivity. Prominent representatives of anabolic-androgenic steroids (AAS) are for instance methyltestosterone, metandienone and stanozolol, which are discussed as model compounds with regard to general pharmacological aspects of synthetic AAS. Recently, nonsteroidal alternatives to AAS have been developed that selectively activate the androgen receptor in either muscle tissue or bones. These so-called selective androgen receptor modulators (SARMs) are currently undergoing late clinical trials (IIb) and will be prohibited by the World Anti-Doping Agency from January 2008. Their entirely synthetic structures are barely related to steroids, but particular functional groups allow for the tissue-selective activation or inhibition of androgen receptors and, thus, the stimulation of muscle growth without the risk of severe undesirable effects commonly observed in steroid replacement therapies. Hence, these compounds possess a high potential for misuse in sports and will be the subject of future doping control assays.
Collapse
Affiliation(s)
- Mario Thevis
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany.
| | | |
Collapse
|
50
|
Bowers LD. The analytical chemistry of drug monitoring in athletes. ANNUAL REVIEW OF ANALYTICAL CHEMISTRY (PALO ALTO, CALIF.) 2009; 2:485-507. [PMID: 20636072 DOI: 10.1146/annurev-anchem-060908-155159] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The detection and deterrence of the abuse of performance-enhancing drugs in sport are important to maintaining a level playing field among athletes and to decreasing the risk to athletes' health. The World Anti-Doping Program consists of six documents, three of which play a role in analytical development: The World Anti-Doping Code, The List of Prohibited Substances and Methods, and The International Standard for Laboratories. Among the classes of prohibited substances, three have given rise to the most recent analytical developments in the field: anabolic agents; peptide and protein hormones; and methods to increase oxygen delivery to the tissues, including recombinant erythropoietin. Methods for anabolic agents, including designer steroids, have been enhanced through the use of liquid chromatography/tandem mass spectrometry and gas chromatography/combustion/isotope-ratio mass spectrometry. Protein and peptide identification and quantification have benefited from advances in liquid chromatography/tandem mass spectrometry. Incorporation of techniques such as flow cytometry and isoelectric focusing have supported the detection of blood doping.
Collapse
Affiliation(s)
- Larry D Bowers
- United States Anti-Doping Agency, Colorado Springs, Colorado 80906, USA.
| |
Collapse
|